Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niacinamide

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Niacinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anemia (phenotype)
  • Folate deficiency
  • Iron deficiency anemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Niacinamide, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA5.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Niacinamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niacinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Meta-analysis of Randomized Controlled Trials on Vitamins and Mineral Supplementation for CVD Prevention and Treatment

    NCT03442283 · start 2016-07

    Registered record
    Registry ID
    NCT03442283
    Conditions
    Cardiovascular Diseases
    Interventions
    Vitamin mineral supplementation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2018-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionVitamin mineral supplementation
    PhaseNot recorded
    Registry statusUnknown

  • Nicotinamide Riboside and Mitochondrial Metabolism

    NCT03951285 · start 2016-05-25

    Registered record
    Registry ID
    NCT03951285
    Conditions
    Obesity
    Interventions
    NR in BMI-discordant twins; NR in BMI-concordant twins
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-05-25
    Completion
    2019-05-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionNR in BMI-discordant twins; NR in BMI-concordant twins
    PhaseNot applicable
    Registry statusCompleted

  • The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

    NCT05121571 · start 2016-04-21

    Registered record
    Registry ID
    NCT05121571
    Conditions
    Hepatocellular Carcinoma
    Interventions
    HAIC; Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-04-21
    Completion
    2021-05-01
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionHAIC; Sorafenib
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Two Nutrition Interventions in Young Children in El Salvador

    NCT02567981 · start 2015-09

    Registered record
    Registry ID
    NCT02567981
    Conditions
    Micronutrient Deficiency
    Interventions
    21 micronutrient-fortified supplement; Cereal Fortificado (Fortified Cereal); Ferrous sulphate; Vitamin A
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-09
    Completion
    2020-09
    Enrolment
    4,577

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicronutrient Deficiency
    Intervention21 micronutrient-fortified supplement; Cereal Fortificado (Fortified Cereal); Ferrous sulphate; Vitamin A
    PhaseNot applicable
    Registry statusUnknown

  • Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    NCT02270788 · start 2015-04-02

    Registered record
    Registry ID
    NCT02270788
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Crenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04-02
    Completion
    2016-10-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCrenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    PhasePhase 1
    Registry statusCompleted

  • Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

    NCT02029001 · start 2014-03

    Registered record
    Registry ID
    NCT02029001
    Conditions
    Malignant Solid Neoplasms
    Interventions
    Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD); Olaparib (300 mg BID); Durvalumab + Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-03
    Completion
    2028-10
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasms
    InterventionNilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

    NCT02015728 · start 2013-12

    Registered record
    Registry ID
    NCT02015728
    Conditions
    Recurrent Childhood Brain Tumor
    Interventions
    Tumor biology testing; Temozolomide; Etoposide; Sorafenib; Everolimus; Erlotinib; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2017-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Brain Tumor
    InterventionTumor biology testing; Temozolomide; Etoposide; Sorafenib +3 more
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

    NCT01747642 · start 2012-12

    Registered record
    Registry ID
    NCT01747642
    Conditions
    Quality of Life
    Interventions
    Oncoxin; Suranix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2014-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionQuality of Life
    InterventionOncoxin; Suranix
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

    NCT01664182 · start 2012-08-01

    Registered record
    Registry ID
    NCT01664182
    Conditions
    Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Bevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate; Trebananib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2020-12-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionBevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate +1 more
    PhasePhase 2
    Registry statusCompleted

  • Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

    NCT01803594 · start 2012-08

    Registered record
    Registry ID
    NCT01803594
    Conditions
    Dyslipidemia
    Interventions
    Krill Oil; Lutein; Nicotinic acid; Dairy phospholipids; Control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-08
    Completion
    2015-03-13
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionKrill Oil; Lutein; Nicotinic acid; Dairy phospholipids +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis

    NCT03518502 · start 2012-03-01

    Registered record
    Registry ID
    NCT03518502
    Conditions
    Hepatocellular Carcinoma; Metastasis
    Interventions
    transarterial chemoembolization (TACE); Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-03-01
    Completion
    2022-02-28
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma; Metastasis
    Interventiontransarterial chemoembolization (TACE); Sorafenib
    PhasePhase 4
    Registry statusUnknown

  • Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease

    NCT01391377 · start 2011-07

    Registered record
    Registry ID
    NCT01391377
    Conditions
    Peripheral Arterial Disease
    Interventions
    Niacin/Laropiprant combination; Sugar pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-07
    Completion
    2014-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Arterial Disease
    InterventionNiacin/Laropiprant combination; Sugar pill
    PhaseNot applicable
    Registry statusTerminated

  • Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

    NCT01258608 · start 2011-02-08

    Registered record
    Registry ID
    NCT01258608
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Mapatumumab; Placebo; Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-02-08
    Completion
    2017-11-29
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionMapatumumab; Placebo; Sorafenib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

    NCT01409499 · start 2011-01

    Registered record
    Registry ID
    NCT01409499
    Conditions
    Hepatectomy; Hepatocellular Carcinoma; Sorafenib
    Interventions
    hepatic resection; transcatheter hepatic arterial chemoembolization; sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-01
    Completion
    2018-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatectomy; Hepatocellular Carcinoma; Sorafenib
    Interventionhepatic resection; transcatheter hepatic arterial chemoembolization; sorafenib
    PhasePhase 4
    Registry statusCompleted

  • Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

    NCT03622541 · start 2010-11-15

    Registered record
    Registry ID
    NCT03622541
    Conditions
    FLT3-ITD Mutation; AML
    Interventions
    Sorafenib 200mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-11-15
    Completion
    2020-03-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFLT3-ITD Mutation; AML
    InterventionSorafenib 200mg
    PhasePhase 2
    Registry statusCompleted